Study
Effects of Omega-3 and Omega-9 Fatty Acid Supplementation on HOMA-IR and Inflammatory Markers in Children with Obesity and Insulin Resistance: A Triple-Blind RCT with Post-Intervention Follow-Up
A triple-blind RCT in 97 children found combined omega-3 plus omega-9 lowered HOMA-IR and insulin, but omega-3 alone showed no significant between-group advantage and effects tracked with weight loss and baseline status.
Summary Can omega-3 supplements improve insulin resistance in children with obesity? Show / hide ↓
Researchers gave 97 children aged 8 to 17 omega-3, omega-9, or both for three months, then followed them for two more months. All the children had overweight or obesity and insulin resistance, meaning their bodies were not responding well to insulin. HOMA-IR, a blood-test estimate of insulin resistance, and insulin levels fell in the omega-9 and combined-supplement groups. Omega-3 alone did not show a clear advantage over the other groups, and there were no significant differences between groups overall. Changes were more closely linked to starting health and weight loss than to which supplement children received.
What this means for you: This study does not support buying omega-3 specifically to improve insulin resistance. It was small, involved children rather than adults, and did not show that one supplement worked better than another.
weak evidenceNinety-seven children aged 8 to 17 with overweight or obesity and insulin resistance (HOMA-IR >3.0) were randomized to omega-3 (n=32), omega-9 (n=34), or combined omega-3 plus omega-9 (n=31) at 1.8 g/day for 3 months, followed by a 2-month follow-up. The primary outcome was change in HOMA-IR from baseline to end of treatment. Fasting insulin and HOMA-IR fell in the combined group (p<0.001) and in the omega-9 group (p=0.010 and p=0.006). At the 5-month follow-up only the combined group maintained significant reductions in both. IL-6 and leptin fell across all groups. However, the intervention group was not an independent predictor of metabolic response in multivariable regression, and there were no significant between-group differences at any timepoint. The authors attribute response magnitude to baseline metabolic status and concurrent BMI reduction rather than to the supplement arm. This is a real human RCT of omega-3, but the outcome is pediatric insulin resistance, not aging, and omega-3 alone did not separate from placebo on the primary comparison.
Within-group reductions in HOMA-IR and fasting insulin persisted after discontinuation only in the Combined group, but without significant between-group differences at any timepoint, consistent with response magnitude reflecting baseline status and adiposity reduction rather than treatment group per se.
Children, not adults; generalizability to longevity supplementation is limited. Omega-3 alone did not show significant between-group advantage on the primary endpoint. Effects confounded by concurrent weight loss. No numerical HOMA-IR or effect-size values reported in the abstract. Three months is short for metabolic outcomes.
Cited by
1 encyclopedia entries reference this study.